Alzamend Neuro Financials
| ALZN Stock | USD 0.85 0.04 4.49% |
With this module, you can analyze Alzamend financials for your investing period. You should be able to track the changes in Alzamend Neuro individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Alzamend |
Understanding current and past Alzamend Neuro Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Alzamend Neuro's financial statements are interrelated, with each one affecting the others. For example, an increase in Alzamend Neuro's assets may result in an increase in income on the income statement.
The data published in Alzamend Neuro's official financial statements usually reflect Alzamend Neuro's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Alzamend Neuro. For example, before you start analyzing numbers published by Alzamend accountants, it's critical to develop an understanding of what Alzamend Neuro's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Alzamend Neuro's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Alzamend Neuro's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Alzamend Neuro's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Alzamend Neuro. Please utilize our Beneish M Score to check the likelihood of Alzamend Neuro's management manipulating its earnings.
Alzamend Neuro Stock Summary
Alzamend Neuro competes with TRACON Pharmaceuticals, Solid Biosciences, Kezar Life, Senti Biosciences, and X4 Pharmaceuticals. Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. Alzamend Neuro operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US02262M3088 |
| CUSIP | 02262M308 02262M407 |
| Location | Florida; U.S.A |
| Business Address | 3480 Peachtree Road |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.alzamend.com |
| Phone | 844 722 6333 |
| Currency | USD - US Dollar |
You should never invest in Alzamend Neuro without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Alzamend Stock, because this is throwing your money away. Analyzing the key information contained in Alzamend Neuro's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Alzamend Neuro Key Financial Ratios
Generally speaking, Alzamend Neuro's financial ratios allow both analysts and investors to convert raw data from Alzamend Neuro's financial statements into concise, actionable information that can be used to evaluate the performance of Alzamend Neuro over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Alzamend Neuro reports annually and quarterly.| Return On Equity | -11.96 | ||||
| Return On Asset | -1.67 | ||||
| Target Price | 25.0 |
Alzamend Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Alzamend Neuro's current stock value. Our valuation model uses many indicators to compare Alzamend Neuro value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Alzamend Neuro competition to find correlations between indicators driving Alzamend Neuro's intrinsic value. More Info.Alzamend Neuro is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Alzamend Neuro by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Alzamend Neuro's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Alzamend Neuro's earnings, one of the primary drivers of an investment's value.Alzamend Neuro Systematic Risk
Alzamend Neuro's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Alzamend Neuro volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Alzamend Neuro correlated with the market. If Beta is less than 0 Alzamend Neuro generally moves in the opposite direction as compared to the market. If Alzamend Neuro Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Alzamend Neuro is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Alzamend Neuro is generally in the same direction as the market. If Beta > 1 Alzamend Neuro moves generally in the same direction as, but more than the movement of the benchmark.
About Alzamend Neuro Financials
What exactly are Alzamend Neuro Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Alzamend Neuro's income statement, its balance sheet, and the statement of cash flows. Potential Alzamend Neuro investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Alzamend Neuro investors may use each financial statement separately, they are all related. The changes in Alzamend Neuro's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Alzamend Neuro's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Alzamend Neuro Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Alzamend Neuro is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Alzamend has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Alzamend Neuro's financials are consistent with your investment objective using the following steps:- Review Alzamend Neuro's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Alzamend Neuro's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Alzamend Neuro's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Alzamend Neuro's stock is overvalued or undervalued.
Alzamend Neuro April 16, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Alzamend Neuro help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Alzamend Neuro. We use our internally-developed statistical techniques to arrive at the intrinsic value of Alzamend Neuro based on widely used predictive technical indicators. In general, we focus on analyzing Alzamend Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Alzamend Neuro's daily price indicators and compare them against related drivers.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 32.62 | |||
| Value At Risk | (7.62) | |||
| Potential Upside | 7.41 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.Note that the Alzamend Neuro information on this page should be used as a complementary analysis to other Alzamend Neuro's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Alzamend Stock analysis
When running Alzamend Neuro's price analysis, check to measure Alzamend Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alzamend Neuro is operating at the current time. Most of Alzamend Neuro's value examination focuses on studying past and present price action to predict the probability of Alzamend Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alzamend Neuro's price. Additionally, you may evaluate how the addition of Alzamend Neuro to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is Alzamend Neuro's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.